search
Back to results

HP011-101, HP828-101, and Standard Care for Pressure Ulcers

Primary Purpose

Pressure Ulcers

Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
HP011-101
HP-828-101
Standard Care
Sponsored by
Healthpoint
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pressure Ulcers

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects must meet all of the following criteria to be eligible for the study:
  • Provide informed consent, or informed assent if less than 18 years of age.
  • Age 12 years or older, of either sex, and of any race or skin type, provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
  • Have a pressure ulcer ≥ 5 cm² and ≤ 100 cm² in area (measured as greatest length x perpendicular width of the area of non-blanching erythema or denuded skin, whichever is greater), and will remain hospitalized for at least three weeks.
  • Are capable of maintaining an adequate nutritional status.
  • All female subjects must have a negative urinary pregnancy test.
  • Have, within 12 weeks prior to screening, clinical laboratory test results indicating:

    • Serum albumin ≥ 3.0 g/dL (30 g/L)
    • Alkaline phosphatase, ALT, AST, BUN and serum creatinine levels < 3x upper limit of the Healthpoint normal range (refer to Section 18.1.2)
    • HbA1C ≤ 12%
    • Hemoglobin ≥ 10 g/dL
  • The most recently obtained values must be evaluated against these criteria. If these values are not available from a blood sample within 12 weeks of screening, blood must be drawn at screening and these laboratory values determined.
  • For ulcers that will require surgical debridement prior to enrollment, the wound must be expected to remain a Stage I or Stage II partial thickness wound after debridement.

Exclusion Criteria:

  • Subjects meeting any of the following criteria are not eligible to enter the study:
  • Have a known hypersensitivity to any of the test articles or their components.
  • Have received therapy with another investigational agent within thirty (30) days of screening.
  • Are pregnant or nursing.
  • Are currently being treated with systemic antibiotics.
  • Have received systemic treatment with glucocorticoids for > 10 consecutive days within 1 month prior to the start of the study.
  • Have received chemotherapy or radiation therapy within the past 5 years.
  • Have clinical evidence of bacterial or fungal infection of the wound per visual/clinical assessment.
  • Have a severe burn, immunodeficiency disorder, hematologic disorder, or metastatic malignancy.
  • Have had documented osteomyelitis in the wound area within 6 months prior to screening.
  • The Principal Investigator may declare any subject ineligible for a valid medical reason.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Active Comparator

    Active Comparator

    Other

    Arm Label

    HP011-101

    HP828-101

    Standard Care

    Arm Description

    Outcomes

    Primary Outcome Measures

    Change in Wound Bed Scores

    Secondary Outcome Measures

    Adverse Events

    Full Information

    First Posted
    December 3, 2010
    Last Updated
    September 10, 2012
    Sponsor
    Healthpoint
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01273428
    Brief Title
    HP011-101, HP828-101, and Standard Care for Pressure Ulcers
    Official Title
    Comparison of HP011-101, HP828-101, and Standard Care in the Management of Stage I-II Pressure Ulcers in Patients With Spinal Cord Injury
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2011
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    The device test article is no longer available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    June 2011 (Anticipated)
    Study Completion Date
    November 2011 (Anticipated)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Healthpoint

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Testing a drug and a device for the treatment of pressure ulcers, compared with current treatments.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pressure Ulcers

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    Care ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    HP011-101
    Arm Type
    Active Comparator
    Arm Title
    HP828-101
    Arm Type
    Active Comparator
    Arm Title
    Standard Care
    Arm Type
    Other
    Intervention Type
    Drug
    Intervention Name(s)
    HP011-101
    Intervention Type
    Device
    Intervention Name(s)
    HP-828-101
    Intervention Type
    Other
    Intervention Name(s)
    Standard Care
    Primary Outcome Measure Information:
    Title
    Change in Wound Bed Scores
    Time Frame
    22 days
    Secondary Outcome Measure Information:
    Title
    Adverse Events
    Time Frame
    22 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    12 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Subjects must meet all of the following criteria to be eligible for the study: Provide informed consent, or informed assent if less than 18 years of age. Age 12 years or older, of either sex, and of any race or skin type, provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments. Have a pressure ulcer ≥ 5 cm² and ≤ 100 cm² in area (measured as greatest length x perpendicular width of the area of non-blanching erythema or denuded skin, whichever is greater), and will remain hospitalized for at least three weeks. Are capable of maintaining an adequate nutritional status. All female subjects must have a negative urinary pregnancy test. Have, within 12 weeks prior to screening, clinical laboratory test results indicating: Serum albumin ≥ 3.0 g/dL (30 g/L) Alkaline phosphatase, ALT, AST, BUN and serum creatinine levels < 3x upper limit of the Healthpoint normal range (refer to Section 18.1.2) HbA1C ≤ 12% Hemoglobin ≥ 10 g/dL The most recently obtained values must be evaluated against these criteria. If these values are not available from a blood sample within 12 weeks of screening, blood must be drawn at screening and these laboratory values determined. For ulcers that will require surgical debridement prior to enrollment, the wound must be expected to remain a Stage I or Stage II partial thickness wound after debridement. Exclusion Criteria: Subjects meeting any of the following criteria are not eligible to enter the study: Have a known hypersensitivity to any of the test articles or their components. Have received therapy with another investigational agent within thirty (30) days of screening. Are pregnant or nursing. Are currently being treated with systemic antibiotics. Have received systemic treatment with glucocorticoids for > 10 consecutive days within 1 month prior to the start of the study. Have received chemotherapy or radiation therapy within the past 5 years. Have clinical evidence of bacterial or fungal infection of the wound per visual/clinical assessment. Have a severe burn, immunodeficiency disorder, hematologic disorder, or metastatic malignancy. Have had documented osteomyelitis in the wound area within 6 months prior to screening. The Principal Investigator may declare any subject ineligible for a valid medical reason.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Herbert B Slade, MD
    Organizational Affiliation
    Healthpoint, Ltd
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Learn more about this trial

    HP011-101, HP828-101, and Standard Care for Pressure Ulcers

    We'll reach out to this number within 24 hrs